F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity. (Q54264719)

27 May 2018

title

F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity. (English)

1 reference

27 May 2018

1 reference

A Kruczynski

1

1 reference

27 May 2018

A Pillon

2

1 reference

27 May 2018

L Créancier

3

1 reference

27 May 2018

I Vandenberghe

4

1 reference

27 May 2018

B Gomes

5

1 reference

27 May 2018

V Brel

6

1 reference

27 May 2018

E Fournier

7

1 reference

27 May 2018

J-P Annereau

8

1 reference

27 May 2018

E Currie

9

1 reference

27 May 2018

Y Guminski

10

1 reference

27 May 2018

D Bonnet

11

1 reference

27 May 2018

C Bailly

12

1 reference

27 May 2018

N Guilbaud

13

1 reference

27 May 2018

publication date

9 April 2013

1 reference

27 May 2018

published in

Leukemia

1 reference

27 May 2018

volume

27

1 reference

27 May 2018

issue

11

1 reference

27 May 2018

page(s)

2139-2148

1 reference

27 May 2018

cites work

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Acute myeloid leukemia: epidemiology and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Age and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Acute myeloid leukemia: focus on novel therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Hallmarks of senescence in carcinogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Apoptosis and the response to anticancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Cellular senescence: when bad things happen to good cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

inferred from DOI database lookup

7 January 2021

based on heuristic

Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.108

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2013.108

1 reference

27 May 2018

1 reference

27 May 2018